Abivax SA Sponsored ADR (NASDAQ:ABVX – Get Free Report) traded down 12.4% on Friday. The stock traded as low as $72.00 and last traded at $70.6430. 507,381 shares traded hands during trading, a decline of 63% from the average daily volume of 1,367,198 shares. The stock had previously closed at $80.65.
Analyst Ratings Changes
A number of analysts recently issued reports on ABVX shares. Truist Financial lowered their price target on Abivax from $155.00 to $151.00 and set a “buy” rating for the company in a research report on Tuesday, September 22nd. Wall Street Zen lowered Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. Piper Sandler reaffirmed an “overweight” rating on shares of Abivax in a research note on Wednesday, October 21st. Barclays reissued an “overweight” rating and set a $148.00 price target on shares of Abivax in a research note on Tuesday, September 22nd. Finally, Wedbush cut their price objective on Abivax from $118.00 to $96.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Abivax has an average rating of “Moderate Buy” and an average target price of $155.00.
Read Our Latest Research Report on Abivax
Abivax Trading Down 8.8%
Abivax (NASDAQ:ABVX – Get Free Report) last issued its quarterly earnings data on Monday, September 21st. The company reported ($1.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.79). The company had revenue of $1.37 million during the quarter, compared to analysts’ expectations of $0.80 million. Research analysts predict that Abivax SA Sponsored ADR will post -4.14 earnings per share for the current fiscal year.
Institutional Trading of Abivax
A number of institutional investors have recently modified their holdings of ABVX. Versant Capital Management Inc bought a new position in shares of Abivax during the 2nd quarter worth approximately $30,000. Assetmark Inc. grew its holdings in Abivax by 41.5% in the first quarter. Assetmark Inc. now owns 886 shares of the company’s stock worth $99,000 after purchasing an additional 260 shares during the last quarter. Troluce Capital Advisors LLC purchased a new position in Abivax in the second quarter worth $133,000. Hantz Financial Services Inc. grew its holdings in Abivax by 22.5% in the third quarter. Hantz Financial Services Inc. now owns 1,296 shares of the company’s stock worth $128,000 after purchasing an additional 238 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in shares of Abivax by 6.1% during the third quarter. HighTower Advisors LLC now owns 2,125 shares of the company’s stock worth $210,000 after purchasing an additional 122 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors.
About Abivax
Abivax is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response. The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation. Founded in 2013, Abivax conducts clinical development internationally.
Read More
- Five stocks we like better than Abivax
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Abivax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abivax and related companies with MarketBeat.com's FREE daily email newsletter.
